Navigation Links
Researchers suggest new way of looking at what causes sepsis
Date:6/23/2011

TORONTO, Ont., June 22, 2011 Researchers at St. Michael's Hospital have put forward a new theory as to what causes sepsis, an often fatal condition that occurs when infection spreads throughout the body.

Leaking blood vessels may actually be a cause of sepsis, rather than a symptom as previously thought, said Dr. Warren Lee.

Dr Lee's hypothesis and a review of recent research on sepsis were published today in the journal Science Translational Medicine.

Sepsis kills about 1,400 people a day worldwide and is the second-leading cause of death in intensive care units in Canada. Despite intense research, the death rate remains high, between 30 and 50 per cent. Treatments largely consist of surgical removal or drainage of the infected site, antibiotics and supportive care.

"The lack of therapies is not for want of effort. On the basis of promising in vitro and animal studies, many drugs have entered clinical trials only to fail, resulting in the description of sepsis research as a 'graveyard' of discovery," said Dr. Lee, a critical care physician and researcher in the hospital's L Ka Shing Knowledge Institute.

"The repeated failure of clinical trials suggests that some fundamental knowledge is lacking in our current understanding of the pathogenesis of human sepsis."

Dr. Lee said one reason previous trials may have failed is that they haven't taken into account a key feature of sepsis in humans -- diffuse microvascular leakage (widespread leakage from small blood vessels) leading to swelling in tissues and organs (edema). This causes organs throughout the body to malfunction. There have been no clinical trials of drugs designed to prevent or treat leaky blood vessels.

"This is a major change in our thinking about sepsis that could lead to novel treatments to save lives," Dr. Lee said. "Sepsis is a devastating illness. If we could develop drugs to stop blood vessels from leaking, we could save lives."


'/>"/>

Contact: Leslie Shepherd
shepherdl@smh.ca
416-864-6094
St. Michael's Hospital
Source:Eurekalert

Related biology news :

1. ORNL researchers win 7 R&D 100 awards
2. Yale researchers pinpoint reasons for dramatic rise in cesarean births
3. U of M researchers find smart decisions for changing environmental times
4. Researchers find process of cervical ripening differs between term and preterm birth
5. Rensselaer researchers secure $2.7 million NIH grant to advance scarless surgery
6. USC researchers find new clues about protein linked to Parkinsons disease
7. GW researchers receive award from NCI to study cancer from a neglected tropical disease
8. MSU plant scientist named one of the nations most innovative researchers
9. Leaky genes put evolution on the fast track, Pitt and UW-Madison researchers find
10. Researchers predict record Gulf of Mexico dead zone due to Mississippi River flooding
11. Researchers identify why dopamine replacement therapy has a paradoxical effect on cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... phase I/II dose escalation and expansion clinical trial for its lead drug candidate, ... The purpose of the trial was to determine the safety, antitumor activity, and ...
(Date:12/7/2016)... Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dan Kephart as its chief science officer ... assume his responsibilities at Neogen effective Jan. 1. ... for the agribusiness unit of Thermo Fisher Scientific, as ... Life Technologies. His extensive industry experience also includes the ...
(Date:12/7/2016)... OTTAWA, Ontario , Dec. 7, 2016 /PRNewswire/ ... partnership with General Atomics (GA), welcome today,s award ... National Nuclear Security Administration (NNSA) of the Phase ... its project with Nordion and the University of ... Phase II funding will support the establishment of ...
Breaking Biology Technology: